{
  "report_rows": [
    {
      "kpi": "Q2 2026 total revenue",
      "prediction": "BEAT",
      "answer": "pred ~$14.55B vs. cons $14.40B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 adjusted diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$0.70 vs. cons $0.68",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Padcev revenue",
      "prediction": "BEAT",
      "answer": "pred ~$650M vs. cons $640M",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 total revenue guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$61.0B midpoint vs. cons $61.0B (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY2026 adjusted diluted EPS guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$2.90 midpoint vs. cons $2.92 (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 1.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.5,
  "day5_path": "STABILIZE",
  "day5_rationale": "A modest ~$0.02 EPS beat versus $0.68 consensus and ~$0.15B revenue beat versus $14.40B should support an initial positive reaction, but unchanged FY2026 EPS guidance of ~$2.90 versus $2.92 consensus leaves no out-period estimate-raise catalyst; recurring-growth validation offsets but does not eliminate pricing, COVID-seasonality, and LOE concerns.",
  "day5_confidence": "MEDIUM"
}